V
Viela Bio
Clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases
About Viela Bio
Viela Bio is focused on developing and commercializing innovative medicines aimed at treating a broad spectrum of autoimmune and severe inflammatory diseases. The company employs a unique approach that targets the underlying molecular causes of these diseases, enabling the development of more precise therapies. This method also helps in identifying patients who are more likely to respond to the treatments and allows for the pursuit of multiple indications for each product candidate. Viela Bio serves patients suffering from autoimmune and severe inflammatory conditions, operating primarily in the biopharmaceutical market. The business model revolves around the research, development, and commercialization of novel therapeutic solutions. Revenue is generated through the sale of these specialized medicines, as well as potential partnerships and licensing agreements with other pharmaceutical companies. Viela Bio's clinical pipeline is robust, with multiple candidates in various stages of development, aimed at addressing unmet medical needs in the autoimmune and inflammatory disease space.
Source: Dealroom company dataAt a glance
- Founded
- 2018
- Headquarters
- Gaithersburg, United States
- Listing
- IPO 2019
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Temasek
Boyu Capital
Hillhouse Capital
6 Dimensions Capital- SCSirona Capital
HBM Healthcare Investments
Cormorant Asset Management
Goldman Sachs
Viking Global Investors
Series B and later1 investor entered at this stage
MedImmune
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Patents
28 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Viela Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Viela Bio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.